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ABSTRACT
Although elevated serum low-density lipoprotein-cholesterol (LDL-C) is without any doubts 
accepted as an important risk factor for cardiovascular disease (CVD), the role of elevated 
triglycerides (TGs)-rich lipoproteins as an independent risk factor has until recently been 
quite controversial. Recent data strongly suggest that elevated TG-rich lipoproteins are 
an independent risk factor for CVD and that therapeutic targeting of them could possibly 
provide further benefit in reducing CVD morbidity, events and mortality, apart from LDL-C 
lowering. Today elevated TGs are treated with lifestyle interventions, and with fibrates which 
could be combined with omega-3 fatty acids. There are also some new drugs. Volanesorsen, 
is an antisense oligonucleotid that inhibits the production of the Apo C-III which is crucial 
in regulating TGs metabolism because it inhibits lipoprotein lipase (LPL) and hepatic lipase 
activity but also hepatic uptake of TGs-rich particles. Evinacumab is a monoclonal antibody 
against angiopoietin-like protein 3 (ANGPTL3) and it seems that it can substantially lower 
elevated TGs levels because ANGPTL3 also regulates TGs metabolism. Pemafibrate is a 
selective peroxisome proliferator-activated receptor alpha modulator which also decreases 
TGs, and improves other lipid parameters. It seems that it also has some other possible 
antiatherogenic effects. Alipogene tiparvovec is a nonreplicating adeno-associated viral vector 
that delivers copies of the LPL gene to muscle tissue which accelerates the clearance of TG-rich 
lipoproteins thus decreasing extremely high TGs levels. Pradigastat is a novel diacylglycerol 
acyltransferase 1 inhibitor which substantially reduces extremely high TGs levels and appears 
to be promising in treatment of the rare familial chylomicronemia syndrome.
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INTRODUCTION
It is well known that elevated serum concentration of low density lipoproteins (LDLs), which 
are lipoprotein particles carrying most of the total circulating cholesterol, and their main 
lipid component low-density lipoprotein-cholesterol (LDL-C), are a well-known risk factor 
for atherosclerotic cardiovascular disease (CVD), particularly for coronary heart disease 
(CHD). It is also generally accepted that both primary and secondary prevention of CVD 
by decreasing elevated LDL-C can decrease CVD morbidity, CVD events and mortality.1)2) 
This is especially true when serum levels of LDL-C are extremely elevated which occurs in 
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patients with familial hypercholesterolemia, either homozygotes or severe heterozygotes.3-6) 
Nevertheless, elevated LDL-C (of course apart from arterial hypertension, cigarette smoking, 
central obesity etc.) cannot explain all CVD events. Among other lipoprotein risk factors 
triglyceride (TG)-rich lipoproteins are repeatedly and extensively investigated as a possible 
independent risk factor for CVD. When discussing the importance of TG-rich lipoprotein 
particles, it has to be mentioned that hypertriglyceridemia is commonly accepted to be 
fasting TGs serum level ≥1.7 mmol/L (≥150 mg/dL).7)8)
The aim of this paper is to critically appraise the current evidence relating to elevated TG-rich 
lipoproteins as a risk factor for CVD and to consider possible therapeutic strategies for their 
management.
METABOLISM OF TRIGLYCERIDE-RICH LIPOPROTEINS
TG-rich lipoprotein particles contain exogenous and endogenous TGs and represent the 
transport module for fatty acids which provide an essential source of energy upon oxidation 
in mitochondria. A major source of TGs is derived from dietary fat consumption. Dietary TGs 
are absorbed by enterocytes in which they combine with apolipoprotein (Apo) B48 to form 
the largest lipoprotein particles – chylomicrons. They are 80–95% built of TGs. Chylomicrons 
are transported first via perimesenteric lymphatic vessels and then enter the blood circulation 
via ductus thoracicus. By moving through circulation chylomicrons acquire Apo C-II, Apo 
C-III, and Apo E. Heart is the first organ for delivery of fatty acids from TG-rich particles to 
fulfil energy requirements.
It has to be stressed that neither TG-rich lipoproteins nor TGs cannot pass through cell 
membranes, including those of endothelial cells. Therefore, intravascular lipolysis is a 
necessary process for release of free fatty acids (FFAs). Chylomicrons and other TG-rich 
particles are hydrolysed by lipoprotein lipase (LPL) along the luminal surface of capillaries. 
LPL is synthesized mostly in macrophages but also parenchymal cells, particularly 
those of the heart, adipose tissue and skeletal muscle. Then, it is transported to the 
endothelial cells surface and secreted into the vasculature of these tissues where it binds to 
glycosylphosphatidylinositol high-density lipoprotein (HDL) binding protein 1 (GPIHBP1).9-11) 
Lipase maturation factor 1 (LMF1) is necessary for the secretion of LPL from the cells and it's 
absence causes severely elevated plasma TG levels.12)
LPL requires activation with Apo C-II, and its activity is highly regulated by various proteins, 
including Apo C-III, Apo A-V, and angiopoietin-like proteins 3 and 4 but also 8 (ANGPTL3, 
4, and 8).13)14) It is important to mention that ANGPTL3 and 4 are well recognized as 
inhibitors of LPL.15) Apo C-II is a 79 amino acid peptide containing 3 amphipathic α-helices 
which is synthetized in hepatic cells. The lipid-binding domain of Apo C-II is located in the 
N-terminal, whereas the C-terminal helix of Apo C-II is responsible for the interaction with 
LPL. Apo C-II circulates in blood on TG-rich lipoprotein particles but also on HDL particles 
and is the rate-limiting protein required for normal LPL activity. One of the possible roles 
of Apo C-II may be to influence binding TG-rich particles to the active site of LPL at the 
endothelial surface.
LPL is also regulated at the level of transcription by both peroxisome proliferator-activated 
receptor (PPAR) α and PPARγ through binding to a peroxisome proliferator response element 
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(PPRE) in the 5′-regulatory region of the LPL gene.16)17) PPARα is involved in lipid metabolism 
in the liver cells, while PPARγ is more involved in adipose tissue lipid homeostasis, thereby 
regulating LPL action. LPL gene single nucleotide polymorphisms (SNPs) are associated with 
TG concentrations but the functionality of many of these SNPs remains poorly understood. 
Relatively recently, it has been shown that different microRNAs (miR-29, miR-1277 and 
miR-410) might be important for posttranslational regulation of LPL. However, their exact 
mechanism(s) has not as yet been elucidated. FFAs which are result of LPL activity are 
then oxidized by a variety of cell types, such as skeletal and myocardial myocytes, or are 
resynthetized together with glycerol in TGs and in this form stored in adipose tissue.18) On 
the other hand, the chylomicron remnants, which are rich in cholesterol esters and Apo E, 
are removed from circulation by binding to the LDL receptors or the LDL receptor-related 
proteins on the liver cells. LMF1 is a gene product that regulates TGs metabolism influencing 
LPL and hepatic lipase (HL).
The liver plays a central role in TGs homeostasis and maintains a steady state between TGs 
synthesis, secretion and oxidation. In contrast to adipose tissue, the liver cells do not store 
TGs under normal physiologic conditions. They can take up FFAs derived from lipolysis in 
adipose tissue or from circulating lipoproteins but may equally synthesize fatty acids from 
carbohydrates in the process of de novo lipogenesis. In the liver cells, fatty acids can be partly 
stored as TGs (particularly in some conditions in lipid droplets - fatty liver) or oxidised to 
generate energy in mitochondria in the process of beta-oxidation. They can also be packaged 
together with glycerol in Apo B100-containing very low-density lipoprotein (VLDL) particles 
which are secreted into the systemic circulation where they serve as a source for energy 
for peripheral tissues. Glycerol-3-phosphate dehydrogenase 1 (GPD1) is needed for TGs 
synthesis. Apo C-I, Apo C-II, Apo C-III, and Apo E are added to the surface of VLDL particles 
during their secretion from liver cells. The molecular pathway involved in the packaging of 
TGs into both chylomicrons and VLDL particles is remarkably similar, involving microsomal 
triglyceride transfer protein (MTTP) as described in detail elsewhere.19)20)
Following secretion, VLDL particles are also hydrolyzed by LPL in the plasma, producing 
progressively smaller VLDL particles and then eventually intermediate-density lipoproteins 
(IDLs). The size of VLDL particles is important since large VLDL particles and chylomicrons 
cannot transverse endothelial barrier and thus cannot start the process of atherogenesis.21) 
However, smaller VLDL and other TG-rich remnant particles which can influx into artery wall 
play an important role and might be, if their concentration in plasma is elevated, a risk factor 
for atherosclerosis and CVD.22)
As just described, during the above explained process, chylomicrons and VLDL particles are 
remodelled so that their TGs are hydrolysed by LPL producing TG-rich remnant particles 
and IDL. The expression “TG-rich lipoprotein remnants” relates to chylomicron and VLDL 
particles which have undergone dynamic remodelling in the plasma after secretion from the 
intestine cells (chylomicrons) or liver cells (VLDL).23)
Some IDL particles are taken up by the liver cells and catabolized in them while some of 
these particles undergo further catabolism by LPL and hepatic TG lipase to generate LDL 
particles. VLDL and LDL, but remnant particles as well, acquire additional cholesteryl esters 
(CEs) in plasma via the action of cholesteryl ester transfer protein (CETP), which exchanges 
TGs in them for CE in HDL. HDL particles have the main role to mediate reverse cholesterol 
transport to the liver. When TGs levels are high, CETP-mediated transfer of TGs from 
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chylomycrons and VLDL to LDL and HDL in exchange for CE from LDL and HDL leads to TG-
enriched VLDL remnants, IDL and small LDL particles. Remnant particles are atherogenic 
primarily as a result of their progressive enrichment with cholesterol during the above 
described process and they are linked to the development and progression of CVD.24-26) It has 
been also shown that that small dense LDL particles are highly atherogenic.27)
WHAT CAN CAUSE ELEVATED CONCENTRATIONS OF 
TRIGLYCERIDE-RICH PARTICLES?
In many patients mild-to-moderate elevated plasma TGs levels are a result of unhealthy diet 
and unhealthy lifestyle, e.g. alcohol overuse. This can also occur due to hypothyroidism, 
pregnancy, hepatosteatosis, weight regain after significant weight loss, nephrotic syndrome 
and some medicines (glucocorticoids, older types of oral estrogens, etc.). Nevertheless, most 
often such elevated levels of TGs occur as a part of the metabolic syndrome and/or type 2 
diabetes (T2D).
Autosomal recessive monogenic severe hypertriglyceridemia is rare. It can result from large-
effect mutations in six different genes either homozygous or heterozygous in combination 
with other lesser genes.28) Two most important forms of genetically elevated TGs are familial 
combined hyperlipidemia (FCHL) and familial hypertriglyceridemia (FHTG). FCHL was 
first described 45 years ago in families of survivors of MI who presented with variable lipid 
disturbances.29) Some of these patients have predominantly elevated plasma total and LDL-C 
and much less elevated TGs, some have elevated TGs alone or predominantly elevated TGs 
and just slightly elevated LDL-C, but most of these patients have elevated both lipids. FCHL 
is characterized by elevated not only TGs levels but also elevated Apo B and an increased 
number of very atherogenic small dense LDL particles but the phenotype of the disease may 
vary even among members from the same family.30) This lipid disturbance is similar to the 
one that occurs in metabolic syndrome and/or T2D. These lipoprotein changes occur as a 
result of overproduction of VLDL particles in liver cells due to an increased Apo B synthesis 
in the setting of disordered adipose metabolism, insulin resistance and accumulation of fat 
in the liver cells, but also due to an impaired clearance of Apo B containing particles.31) Long 
residence time of VLDL particles in the circulation favors the formation of very atherogenic 
small dense LDL particles. FCHL is a multigenic disease with insulin resistance in the 
background. No single genes have been identified or confirmed so far to be the cause of it.
FHTG is also an inherited disease. It occurs because of an increased TGs synthesis, where 
normal numbers of very large TG-enriched VLDL particles are secreted.31) Patients have 
elevated VLDL levels, but kept normal levels of LDL-C and high-density lipoprotein-
cholesterol (HDL-C). Therefore, patients are generally asymptomatic unless extremely 
elevated levels of TGs cause acute pancreatitis, which is often. FHTG is an extremely rare 
lipoprotein disorder caused by mutations in at least 5 genes of the LPL complex. Most 
recently 5 novel pathogenic mutations have been identified: 2 in LPL, 1 in GPIHBP1, and 2 in 
the APOA5 gene but the possibility of involvement of new genes in the manifestation of this 
disease cannot be excluded.32) Extremely elevated levels of TGs cause often acute pancreatitis. 
Recently it has been developed a pragmatic clinical scoring, by standardizing diagnosis, 
which may help differentiate FHTG from multifactorial chylomicronemia syndrome (MCS), 
which may alleviate the need for systematic genotyping in patients with severely elevated TGs 
and may help identify high-priority candidates for genotyping.33)
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Familial dysbetalipoproteinemia (type III hyperlipoproteinemia or remnant removal disease) 
is a rare disease as well. Most patients are homozygous for the E2-isoform of Apo E which 
is important for hepatic clearance of chylomicron TG-rich remnant particles and IDL.34) 
Patients often develop a characteristic clinical syndrome in which both total cholesterol 
and TGs are extremely elevated, usually both in the range of 7–10 mmol/L with an increased 
risk of CVD but it seems that a multigenic background is needed to convert E2/2 to type III 
hyperlipoproteinemia.
As mentioned earlier, elevation of TGs levels could be also caused by polygenic effect of 
multiple genes influencing both VLDL production and removal. So far rare mutations in 
6 genes (LPL, APO C2, APO A5, LMF1, GPIHBP1, and GPD1) with monogenic effect have 
been recognized. They lead from mild up to very severe elevation of serum TGs due to the 
disruption of the chylomicron removal pathways. Extremely high TGs occur in patients who 
are homozygous or compound heterozygotes for mutations of the LPL and in the other genes 
linked to catabolism of TGs rich lipoproteins. Gain of function mutation in APO C-III leading 
to high Apo C-III levels can also cause severely elevated plasma TGs.35) Apo C-III exerts its 
atherogenic action by attenuating lipolysis of TG-rich particles through LPL inhibition that 
results in increased circulating levels of VLDL and chylomicrons.36) Elevated levels of Apo 
C-III are present in patients with very high plasma TGs and have been causally associated 
with metabolic syndrome and insulin resistance.37)
Apo A-V also plays a role in stabilizing the lipoprotein–enzyme complex thereby enhancing 
lipolysis. Therefore, defective or absent Apo A-V can result in reduced efficiency of LPL-
mediated lipolysis and, subsequently increased number of TG-rich particles. A number of 
genes involved in TGs metabolism do have a pleiotropic nature and are also Apo B genes, 
so the metabolism of TG-rich particles and Apo B lipoprotein particles is closely related. 
For example, PCSK9 markedly increases intestinal TGs-rich Apo B containing particles 
production through mechanisms mediated in part by transcriptional effects on Apo B, 
microsomal TG transfer protein, and lipogenic genes and in part by posttranscriptional 
effects on the LDL receptor and microsomal TG transfer protein.
Genome-wide association studies (GWAS) of patients with elevated TGs revealed that 
common variants in Apo A-V, glucokinase regulator (GCKR) which plays an important roles 
in the regulation of glucokinase (GK) activity and the metabolism of glucose and lipids, LPL 
and Apo B genes were associated with the elevated TGs at genome-wide significance and rare 
variants in these four genes explained 1.1% of total variation in patients with elevated TGs.38)
WHY ARE ELEVATED TRIGLYCERIDE-RICH 
LIPOPROTEINS A RISK FACTOR FOR CARDIOVASCULAR 
DISEASE?
Severely elevated TGs, defined by the 2014 National Lipid Association guidelines as a TGs 
level of ≥500 mg/dL (≥5.6 mmol/L), are not only connected with higher CVD risk but are a 
well-established risk factor for acute pancreatitis which can be a life-threatening disease.39)40) 
Moderately elevated TGs are supposed to be a risk factor for CVD as well, even in patients 
treated effectively with statins to reduce LDL-C.41)42) This has been confirmed in a most recent 
study the results of which have shown that despite well controlled LDL-C levels with statins, 
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CVD events were greater among patients with diabetes and elevated TGs levels. Since in 
this study the patients were controlled for all other cardiometabolic risk factors, it might be 
concluded that the difference in TGs levels contributed to the excess CVD risk observed in 
patients with elevated TGs.43)
Epidemiological studies
The traditional view has been that, while elevated concentration of TG-rich particles may be 
associated with increased CVD risk, the association is weakened when adjustment is made 
for other risk factors, particularly HDL-C.44) Indeed, elevated TGs are often accompanied with 
low HDL-C levels. Many studies have looked whether elevated TGs and/or decreased HDL-C 
are responsible for increasing the risk of CVD. For instance, one of them was published most 
recently indicating that 25% of 1,720 apparently healthy 50-year-old men with the highest TG/
HDL-C plasma concentration ratio developed more CVD over the next 40 years, compared 
with those not meeting the point which was the highest quartile >1.8 mmol/L.45) However, 
even after the adjustment for HDL-C, elevated TGs remained a risk factor for CVD and it was 
established that TGs levels and small dense LDL particles could be caused by two different 
genetic loci in FHTG.46) Issues regarding the relevance of HDL-C concentration for CVD have 
been raised and today most authors consider not the low concentration but the disturbed 
functionality of HDL particles are important for CVD. Nevertheless, firm validated data for 
HDL particles functionality are still lacking.23) The nature of the association between elevated 
plasma levels of TG-rich particles and CVD remains still to a certain extent controversial 
and the understanding was for long time that if TGs are at all associated with CVD, the 
relationship is clearly not a linear one as it is with total cholesterol or LDL-C. Elevated levels 
of TGs-rich particles are commonly associated with diabetes and/or metabolic syndrome.47) 
The general view was that correlation with these and other risk factors including low HDL-C, 
smoking, overweight/obesity and hypertension could explain the association with CVD, 
apart from elevated LDL-C levels. This was and still is a problem because many authors 
have attributed the effects of co called “atherogenic dyslipidemia” characterized by elevated 
TGs, low HDL-C and increased number of small dense LDL particles primarily to other lipid 
components and not so much to elevated plasma levels of TG-rich particles.23)
Still, evidence for a role of TGs as an independent risk factor accumulated during last 30 
years.48) An early meta-analysis of 6 studies reported univariable relative risks (RRs) for 
CHD of 1.32 and 1.76 per 1 mmol/L increase in TGs for men and women respectively. These 
RRs attenuated on multivariable adjustment to 1.14 and 1.37, but remained statistically 
significant.49) A much larger meta-analysis involving a total of 10,158 incident CHD cases 
from 262,525 participants in 29 studies showed that moderately strong associations exist 
between TGs concentrations and CHD risk.50) However, there were studies which reported 
loss of statistical significance after correction for other risk factors such as diabetes, body 
mass index, glucose, hypertension, and smoking. In spite of this, the results of these studies 
also suggested that even slightly elevated TGs levels are associated with a higher risk of 
recurrence of CVD events in statin-treated patients and should be considered a useful marker 
of risk.51)
An analysis based upon the Chinese Multi-provincial Cohort Study in which 30,378 
participants were followed for 15 years showed that higher TGs predicted CHD and lower 
HDL-C predicted ischemic stroke only in patients with low LDL-C levels.52) This implies 
that active management of disturbed other lipid fractions, including TGs, is of particular 
importance in those subjects who do not have simultaneously also elevated LDL-C.
1102https://e-kcj.org https://doi.org/10.4070/kcj.2018.0343
Triglyceride-Rich Lipoproteins and New Tretments
Accumulating evidence from epidemiological and genetic evidence supporting elevated 
plasma levels of remnant particles, or TG-rich lipoproteins as an additional cause of CVD 
has driven in recent years renewed interest in this type of dyslipidemia.53) Therefore, today 
it is generally considered that elevated levels of TGs-rich lipoproteins, associated with 
atherogenic dyslipidemia, are one of the major contributors to lipid-related CVD risk.1)47)54)
This was confirmed by an analysis based upon a very large cohort of 86,476 Korean subjects 
who had undergone a general health checkup at Asan Medical Center between January 
2007 and June 2011 and in which CVD events and death were gathered from the nationwide 
health insurance claims database and death certificates using International Classification 
of Diseases-10 codes. The results of this survey suggest that elevated TGs are indeed 
independently associated with an increased risk for CVD, for major CVD events, major 
ischemic heart disease events, and overall CVD events even after adjustment for multiple 
risk factors including HDL-C. This was especially so in non-obese, normotensive, or non-
diabetic subjects.55) At about the same time the results of Circulatory Risk in Communities 
Study also showed that non-fasting TGs are predictive of risk of ischemic CVD in Japanese 
subjects of both sexes.56) These results are similar to the results obtained on European 
populations showing that high TGs, even in subjects with favorable HDL-C levels, may 
identify a subset of subjects who have an increased risk for CVD.57) It has also been shown 
that in patients with proven CHD, higher TGs are independently associated with increased 
22-year all-cause mortality. Even in patients with relatively low TGs of 100 to 149 mg/
dL (up to 1.13–up to 1.7 mmol/L), the increased risk for death could be detected than in 
patients with higher TGs levels. Above this, differently from what was considered for several 
decades, the 22-year mortality risk for patients with severely elevated TGs was significantly 
increased by 68% when compared with patients with low-normal TGs (<100 mg/dL or up to 
1.13 mmol/L).40)
Nevertheless, the results of Emerging Risk Factors Collaboration meta-analysis suggested 
that the association between TGs and CVD risk was abolished when adjustment was made for 
HDL-C, non-HDL-C and other lipids.58) The results of this study were the main reason why 
for a number of years TGs were not much investigated as the possible causative risk factor of 
CVD and their role was quite neglected. On the other hand, more recent data from the same 
group were totally different – they strongly favor the causal association between TG-mediated 
pathways and CHD.59) A meta-analysis of 17 prospective studies with 2,900 CHD endpoints 
revealed that an increment of 1 mmol/L in fasting TG levels was associated with a 14% 
increase in CVD risk.49)
An important study published 2 years ago was the first one to show that lower plasma levels 
of TGs were associated with plaque regression across broad categories of CVD risk.60)
On the other side, recently there is an increased interest in triglyceride-rich lipoprotein 
cholesterol (TRL-C). So in a post-hoc analysis from TNT trial it has been shown that 
increased TRL-C levels were associated with an increased CVD risk and provided evidence 
for the CVD benefit of lipid-lowering with statins among CHD patients with high TRL-C.61) 
Also, it has been shown that increased levels of remnant-like particle cholesterol (RLP-C) 
and triglycerides in low-density lipoprotein (LDL-TG) were predictive of CVD and associated 
with Apo E variants. These authors have concluded that LDL-TG may represent a marker of 
dysfunctional remnant lipoprotein metabolism associated with increased CVD risk.62)
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Genetic studies
A support for a causative role of TG-rich lipoproteins in CVD arises from genetic studies. 
These studies equally indicate that remnant particles, which represent the partially degraded 
products of TG-rich lipoprotein particles (i.e. chylomicrons and VLDL), play a key role in the 
pathophysiology of atherosclerotic CVD.59)63-65)
Genetic studies have showed already several years ago that elevated TGs are causal factor for 
CVD.64) A Mendelian randomization study published a year later (which is a method of using 
measured variation in genes of known function to examine the causal effect of a modifiable 
exposure on disease in non-experimental studies), based on data from the Copenhagen 
City Heart Study found that individuals with genetically confirmed reduction in non-fasting 
plasma TGs had reduced all-cause mortality.66) The idea of this study was to test whether 
low concentrations of non-fasting TGs were associated with reduced all-cause mortality in 
observational analyses (n=13,957) and whether genetic variants in the TG-degrading enzyme 
LPL, resulting in reduced nonfasting TGs and remnant cholesterol, were associated with 
reduced all-cause mortality (n=10,208). Indeed, a plethora of epidemiological evidence exists 
(some of them were mentioned earlier in this text), demonstrating that both fasting and 
nonfasting TGs levels are significant predictors of CVD events, even in individuals who have 
already achieved recommended LDL-C levels with lipid-lowering therapy.67)68)
The results of another Mendelian randomization study using multiple instrumental variables 
supported a causal effect of TG-rich particles on CHD risk as well, but a causal role for low 
HDL-C, though possible, remained less certain.65)
In the DiscovEHR human genetics study performed on 42,930 subjects of mainly European 
ancestry, carriers of the E40K variant of ANGPTL4, which is known to be associated with 
reduced plasma TGs levels and CHD risk, had 13% lower TGs levels than non-carriers. 
Carriers of E40K and other inactivating mutations in ANGPTL4 had also a 19% lower risk of 
CHD than did non-carriers suggesting that lower CHD risk is hinted with gene variants linked 
to lower TGs.69) Another analysis of 72,868 patients with CHD and 120,770 controls who did 
not have CHD also showed decreased TGs levels and increased CHD protection in those with 
vs. without ANGPTL4 mutations.70) The results of both of these studies also suggested that 
TGs might play a causal role in the CHD.
LIFESTYLE INTERVENTIONS
Elevated number of plasma TG-rich particles can be reduced by lifestyle interventions much 
more effectively than elevated LDL-C. The main interventions include reducing excessive 
body weight, and there are many studies suggesting that weight loss is one of the most 
important and effective approach to lower the elevated TGs, no matter which method was 
used to achieve it.71)72) Crucial is also diet. In diet it is important to reduce the intake of mono- 
and disaccharides and total abstinence or reducing to minimum alcohol intake.73) Of course, 
reducing the amount of carbohydrates, especially sucrose and/or high-fructose corn syrup is 
very important. Fructose consumption causes hepatic de novo lipogenesis and elevated TGs 
levels.74) Although high fructose intake is not advisable for patients with elevated number of 
TG-rich particles in plasma, surprisingly a recently published meta-analysis showed that high 
intake of fruit but not vegetables is inversely associated with elevated levels of TGs.75)
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Higher risk for CHD with increasing sugar-sweetened beverages consumption has 
been clearly proven but is often forgotten when giving advices to the patients or healthy 
individuals.76)77) The explanation might be that high fructose corn syrup, a sweetener used 
to flavor soft drinks (much more commonly used for this purpose in the US and some 
other parts of the world than in Europe), increases dietary glycemic load and serum TGs 
levels, and may increase insulin resistance.78) However, low-calorie beverages are associated 
with lower free sugar intake without affecting the intake of other macronutrients or 
negatively impacting cardiometabolic risk factors.79) Physical activity (PA) is also essential 
in decreasing the number of TG-rich particles.80) For instance Personal Activity Intelligence 
(PAI), a personalized metric of PA tracking could help in estimating the effects of PA. In a 
study performed on 3,133 patients with CVD obtaining a weekly PAI score of at least 100 
was associated with lower mortality risk from CVD and all causes in individuals with CVD 
regardless of whether the current PA recommendations were met.81) On the other hand, it 
has been shown that prolonged sitting contributes to CVD risk while intermittent resistance 
activity can mitigate this detrimental effect of prolonged unbroken sitting in overweight and 
obese adults.82) Some authors suggest that appropriately tailored exercise regimen for every 
CVD risk patient should be planed and exercise prescription given to patients with CVD risk 
factors, including elevated plasma TG-rich particles.83)
WHICH DRUGS ARE USED TODAY TO DECREASE THE 
PLASMA CONCENTRATION OF TRIGLYCERIDE-RICH 
PARTICLES?
While statins are without any doubt effective in lowering elevated LDL-C, evidence from 
the VOYAGER analysis discussed in Landmark study, show that even with high-dose, high-
intensity statin therapy, about 50% of patients with elevated TGs do not reach desirable levels 
of TGs (<1.7 mmol/L or up to 150 mg/dL).84) This is quite comprehensible since statins are the 
drugs which are primarily used to lower elevated LDL-C. It is well known that their effects on 
lowering elevated TGs are more than modest. However, it has been shown that atorvastatin 
can significantly lower levels of TG-rich remnant lipoproteins and favorably change LDL 
particle size (from small dense particles to larger, less atherogenic) when TGs levels are high 
(Karlson). In spite of all this, a recent meta-analysis showed that statins significantly decrease 
Apo C-III levels which would indicate a more important role of statins in decreasing elevated 
plasma levels of TG-rich particles.85)
On the other hand, fibrates are the drugs of choice for elevated TGs. Their lipid-modifying 
effects are mediated primarily via interaction with PPARα.23) The results of monotherapy with 
fibrates (Helsinki Heart Study), or more precisely with gemfibrozil, which according to its 
structure is not a fibrate but has a TGs-lowering effect like fibrates, indicated a reduction in 
nonfatal MI and revascularization, with no effect on stroke or CV death. However, the results 
of this trial could not prove neither morbidity nor mortality reduction.86) In FIELD study 
fenofibrate did not significantly reduce the risk of the primary outcome of coronary events - 
CHD death or non-fatal MI but it did reduce total cardiovascular (CV) events, mainly due to 
fewer non-fatal MI and revascularisations.87) A most recent substudy of FIELD showed that 
fenofibrate was not associated with improved carotid IMT in adults with T2D when compared 
with placebo, despite a statistically significant improvement in all lipid parameters, including 
TGs at 4 months and 2 years.88) In Veterans Affairs HDL Intervention Trial (VA-HIT), which 
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was, as the name says, primarily directed towards increasing HDL-C with gemfibrozil, during 
the treatment only the increase in HDL-C, but not the decrease of TGs levels, significantly 
predicted a lower risk of CHD events by multivariable analysis.89) These results were 
subsequently confirmed by a meta-analysis published several years later.90)
Neither the Bezafibrate Infarction Prevention (BIP) study, the large randomized outcomes 
study dealing with secondary prevention, could prove any significant benefit with bezafibrate 
in high risk patients for the primary outcome which was a composite of fatal and nonfatal MI 
plus sudden death.91)
However, a most recently published meta-analysis which included 13 trials and 16,112 
patients showed with a moderate level of evidence a protective effect of the fibrates compared 
with placebo as regards a compound objective of non-fatal stroke, non-fatal myocardial 
infarction, and CVD death.92)
Although fibrates stimulate FA oxidation, suppress FA and TGs synthesis, and reduce plasma 
TGs or TG-rich lipoprotein levels,93) different studies showed inconsistent results regarding 
the effects of PPARα agonists on glucose metabolism.94)95)
Fibrates are almost never used as monotherapy for CVD prevention but are most often 
combined with statins. This is stressed in the most recently published position paper in 
which such a combination is recommended for patients who have elevated TGs plus low 
HDL-C.96) The benefit of combination treatment with fenofibrate plus simvastatin in the 
Action to Control Cardiovascular Risk in Diabetes (ACCORD)97) lipid study was limited 
to the subgroup of patients with atherogenic dyslipidemia (elevated TGs and low plasma 
concentration of HDL-C).98) Both fibrates and statins are associated with an increased risk 
of myopathy.99) However, unlike statin therapy which is not associated with a significant 
alteration of plasma homocysteine levels, fenofibrate increases the homocysteine levels.100) 
Therefore, it could be expected that the risk should be particularly increased when they are 
co-administered, especially if the doses of a statin are very high. However, in the ACCORD 
trial, as in other published studies, combination of fenofibrate and simvastatin did not 
increase the incidence of myopathy, myozitis or rhabdomyolysis.97) Nevertheless, gemfibrozil 
should not be combined with statins since the risk of myopathy in this combination is 15-
fold higher because it increases exposure to and reduces the renal clearance of statins by 
inhibiting their glucuronidation.
Omega-3 fatty acids (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], and 
docosapentaenoic acid) decrease TGs levels when applied in doses of 2–4 g/day. It has to 
be mentioned that omega-3 fatty acids can decrease Apo C-III which can be one of the 
mechanisms to achieve this.101) However CVD outcome studies with omega-3 fatty acids have 
produced inconsistent results. A meta-analysis including data from 63,030 patients from 20 
clinical trials demonstrated that treatment with omega-3 fatty acids did not have an impact 
on a composite CVD end point or total mortality but was associated with a significantly 
decreased rate of vascular death.102) Most recently published results of the ASCEND study 
performed on 15,480 patients with diabetes but without evidence of CVD who received 1,000 
mg capsules containing either omega-3 fatty acids or matching placebo (olive oil) daily could 
not find any significant difference in the risk of serious CVD events between those who were 
assigned to receive omega-3 fatty acid supplementation and those who were assigned to 
receive placebo.103) Similar results were obtained in a most recent Cochrane systematic review 
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which was the most extensive systematic assessment of effects of omega-3 fats on CVD to 
date. Moderate- and high-quality evidence suggests that increasing EPA and DHA has little 
or no effect on CVD mortality nor does it reduce the risk for CVD events, deaths from CHD, 
strokes, or cardiac arrhythmias (evidence mainly from supplement trials). This analysis 
encompassed findings of 79 studies involving more than 112,000 subjects. Low-quality 
evidence suggests that alpha linolenic acid (ALA) may slightly reduce CVD event risk, CHD 
mortality and arrhythmia.104)
The results of ongoing Statin Residual Risk Reduction With Epanova (a mix of omega-3 
FFAs, not requiring co-ingestion with food, which can lower TGs by up to 31%) in STatin 
Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with 
Hypertriglyceridemia (STRENGTH) trial which is evaluating the treatment with EPA plus 
DHA will provide some more answers concerning the effects on TGs and CVD outcomes in 
patients with high CVD risk.105)
Prescription icosapent ethyl (IPE, Vascepa) is a high-purity EPA agent which lowers TGs 
levels but does not increase LDL-C levels which some of the prescription EPA and DHA 
preparations do.106)107) Therefore the results of ongoing REDUCE-IT trial are eagerly awaited. 
This is a phase 3b randomized, double-blinded, placebo-controlled trial with IPE vs. placebo 
and its main objective is to evaluate whether treatment with IPE could reduce ischemic 
events in statin-treated patients with high TGs at elevated CVD risk.108) Most recently a 
structurally engineered new more potent form of omega-3 fatty acids – icosabutate, seems 
to be promising in lowering TGs since it reduced TGs for 27.0%,109) but there are no data on 
possible CVD prevention benefit of this substance so far.
WHAT DO THE GUIDELINES AND POSITION PAPERS SAY?
The most recent American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines on the assessment of CVD risk do not mention TGs at all.110) The guidelines point 
out also, which has been already mentioned earlier in the text, that severely elevated TGs 
such as >1,000 mg/dL (up to 11 mmol/L) which is generally associated with genetic disorders 
of TGs metabolism or according to the 2014 National Lipid Association guidelines even TGs 
level of ≥500 mg/dL (≥5.6 mmol/L), which are often exacerbated by secondary causes, are an 
important risk factor for acute pancreatitis. Other relatively recently published guidelines, 
such as European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) 
guidelines for the management of dyslipidemias and European guidelines on CVD prevention 
in clinical practice (version 2012), do not include TGs in CVD risk estimation neither they 
recommend any specific target value for treatment of elevated TGs levels. However, they 
suggest that those with a TGs level of >1.7 mmol/L (or >150 mg/dL) should be considered 
as increased risk.7)111) The reason is, among others, because elevated TGs are very often 
associated with decreased HDL-C, but also with increased number of very atherogenic small 
dense LDL-particles so it is difficult to discriminate which of these lipid parameters is really 
an important and independent CVD risk factor. This is probably the main reason why the 
guidelines do not mention elevated TG-rich particles as an independent CVD risk factor.112)
A relatively low level of understanding among both physicians and the general public of the 
importance of elevated TGs and decreased HDL-C as CVD risk factors has been pointed 
out as one of the reasons for inadequate treatment of so called ‘residual’ CVD risk. Namely, 
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‘residual’ CVD risk is partially attributed exactly to elevated plasma TG-rich particles and low 
HDL-C.113)114) This is despite the fact that several important position papers were published in 
the last 10 years.23)47)114)115)
The guidelines do not mention neither the importance of elevated TGs and/or low HDL-C in 
the ethiopathogenesis of microvascular changes. This is in spite of the fact that it has been 
shown that not only macrovascular changes causing CVD but also microvascular changes are 
associated with higher levels of TGs and decreased HDL-C, particularly in patients with T2D 
who have good control of LDL-C. These results implicate the role of elevated TGs and low 
HDL-C in diabetic nephropathy and retinopathy as well.116)
The burden of elevated plasma levels of TGs as an important CVD risk factor is highlighted by 
the fact that 34.7% of patients with CVD have elevated TGs.117) A number of recently published 
review papers and editorials suggest also that therapeutic targeting of TG-rich particles 
could possibly provide further benefit in reducing CVD risk and events, apart from LDL-C 
lowering.115)118)
NOVEL POSSIBILITIES FOR ANTI-ATHEROSCLEROTIC 
THERAPY BY LOWERING TRIGLYCERIDE
Since it has been proven that carriers of mutations disrupting Apo C-III function presented 
40% lower risk for CHD compared to non-carriers,119) Apo C-III is considered as a new target 
for lowering TGs.119) Namely, as stated earlier, Apo C-III has a critical role in regulating 
clearance of TGs-rich lipoproteins but also exerting its direct atherogenic effect of provoking 
pro-inflammatory responses in vascular cells, including monocytes and endothelial cells,35) 
although these effects have been questioned by some authors.
Volanesorsen is a second generation antisense oligonucleotid (ASO) that acts to reduce the 
levels of Apo C-III messenger RNA. By acting through ribonuclease H1, volanesorsen induces 
the degradation of the target mRNA and thus inhibits the production of the Apo C-III. As 
already explained, this glycoprotein plays a regulative role on lipoprotein metabolism and 
SNPs in the Apo C-III gene are emerging as a cause of severely elevated TGs. A recent meta-
analysis found evidence that 2 SNPs in Apo C-III are associated with increased CHD risk. 
In specific two polymorphisms, SstI and T-455C, increased the odds for CHD development 
by up to 48 and 77%, respectively.120) The production of Apo C-III is suppressed by the 
ribonuclease H1-mediated degradation of the target mRNA.121) In a randomized, double-
blind, placebo controlled, dose-ranging phase II study this drug as monotherapy lowered 
of Apo C-III which was followed by significant reductions in TGs levels by 31.3 to 70.9%.122) 
No drug-drug interactions were noted because of different mechanism of action and drug 
metabolism. Apart from TGs reduction, HDL-C increased, and VLDL-C decreased in a dose-
dependent manner. All these promising effects were accompanied by a good safety profile. 
In another study volanesorsen was when compared with placebo associated with around 
80% (82.3±11.7%, 81.3±15.7%, and 80.8±13.6%) reduction in Apo C-III-Apo B100, Apo 
C-III-Lp(a) and Apo C-III-Apo A-I lipoproteins respectively after 92 days of follow-up.123) In 
the most recently published ReFOCUS study volanesorsen during a median of 222 days also 
significantly improved the quality of life of patients by reducing the number of symptoms per 
patient across physical, emotional, and cognitive domains but also steatorrhea, pancreatic 
pain, and constant worry about an attack of abdominal pain and/or acute pancreatitis.124) 
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This is important because patients with FHTG experience multiple physical, emotional, and 
cognitive symptoms on a daily to monthly basis. For example, according to the most recent 
analysis, 40% were admitted to the hospital in the past year, lifetime mean of 13 episodes 
occurred in the 40% of patients with acute pancreatitis due to this disease, more than 
90% patients found managing fat intake to be difficult, and 53% experienced symptoms 
despite adherence to their diets.125) There is a number of ongoing studies with volanesorsen 
(APPROACH, COMPASS, etc.).126)
Selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα agents) 
are other potential targets for TGs lowering. In patients with high TGs and low HDL-C, the 
first of these agents pemafibrate (K-877) decreased TGs between 30.9% and 42.7%, increased 
HDL-C, and improved other lipid parameters without increasing adverse effects, as compared 
to placebo and fenofibrate.127)128) It seems that pemafibrate also enhances reverse cholesterol 
transport from macrophages to HDL particles and exerts anti-inflammatory activities thus 
possibly retarding the progression and even promoting the regression of atherosclerosis.129)130) 
Pemafibrate also improves insulin sensitivity by splanchnic glucose uptake from baseline 
in patients with elevated plasma TGs.131) In a head-to-head comparison pemafibrate has 
fewer adverse effects on kidney/liver-related laboratory tests and fewer adverse drug 
reactions, including those leading to treatment discontinuation, over fenofibrate 200 mg/
day.132) It seems that pemafibrate is approximately 10,000-fold more potent than fenofibrate 
in vitro, that it has a greater lipid-modifying efficacy at considerably lower doses both in 
animal models for obesity/T2D and in humans, and is associated with an improved safety/
tolerability profile. In addition, pemafibrate 100 μg BID is associated with beneficial changes 
in markers for liver disease. This suggests that, in addition to improving lipid parameters in 
people with cardiometabolic diseases, pemafibrate might also be useful for the prevention 
of NASH/NAFLD.133) A major outcomes study with pemfibrate in the Pemafibrate to Reduce 
cardiovascular OutcoMes by reducing triglycerides IN diabetic patiENTs (PROMINENT) 
trial on about 10,000 high CVD risk T2D patients with elevated TGs and low HDL-C despite 
concomitant intensive statin treatment has been recently announced.134)
The dual PPAR-α/PPAR-δ agonist GFT-505 has shown favorable results in improving 
atherogenic dyslipidemia and insulin resistance and appears to be a potential candidate not 
only for decreasing elevated TG-rich particles but even more for the treatment of NAFLD.135)
Another substance which is promising in reducing extremely high TGs levels is alipogene 
tiparvovec (AAV1-LPLS447X), a nonreplicating and non-replacing adeno-associated viral 
vector that delivers copies of the human LPL gene to muscle tissue which accelerates the 
clearance of TG-rich lipoproteins. This drug has been approved by European Medicines 
Agency in Europe but only for adult patients diagnosed with familial LPL deficiency and a 
history of multiple or severe episodes of pancreatitis who have failed dietary therapy. The 
application is intramuscular and although a causal relationship could not be established 
and despite the limited number of individuals evaluated, results from a relatively recently 
published study suggest that treatment with this substance was associated with a lower 
frequency and severity of pancreatitis events, and a consequent overall reduction in health 
care resource use up to 6 years post-treatment.136)
Although gene therapy is a logical therapeutic approach to homozygous familial LPL 
deficiency for which current therapies are inadequate, two companies have stopped their 
trials based upon such a treatment. Since rare mutations in APOA5 are associated with 
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increased plasma TGs and premature myocardial infarction, Apo A-V supplementation gene 
therapy might be a prevention option for patients with chronic elevation of TGs who have low 
plasma Apo A-V due to a proven APOA5 mutation/polymorphism and do not have deleterious 
mutations/polymorphisms in other genes known to influence plasma TGs. So far there are no 
published clinical results that could prove this approach.
Pradigastat is a novel diacylglycerol acyltransferase 1 (DGAT1) inhibitor which substantially 
reduces extremely high TGs levels and seems to be promising in treatment of the rare 
familial chylomicronemia syndrome (FCS).137) Since DGAT1 catalyzes the final step in TGs 
synthesis and is highly expressed in the small intestine enterocytes, where it plays a key role 
in absorption of dietary fat, DGAT1 inhibition is an attractive strategy to reduce the synthesis 
and secretion of TGs, and thereby lower plasma TGs. It is important to stress that pradigastat 
was generally well tolerated in patients with FCS who were on very low fat diet at daily doses 
up to 40 mg for 3 weeks and they had only mild to moderate gastrointestinal adverse effects 
like diarrhea, flatulence and abdominal pain. It has to be mentioned that 2 other companies 
ended their DGAT1 inhibitor programs because of gastrointestinal adverse effects.
Recent data based upon a genome-wide association study which included about 2.5 million 
SNPs from 3,041 Japanese healthy volunteers indicate that proprotein convertase subtilisin/
kexin 7 (PCSK7) may be associated with TGs, and may serve as a candidate for a new drug 
target to treat elevated TGs.138) However, so far there is no substance which was tested for 
this. Another treatment possibility is based upon the fact that fibroblast growth factor 21 
(FGF21), an endocrine factor secreted mainly by the liver in response to PPARα activation, 
can lower TGs. This substance achieves this effect most probably by a dual mechanism, 
balancing effects in white adipose tissue (predominantly involved in energy storage and 
mobilization) and brown adipose tissue (involved in non-shivering body thermogenesis).139) 
Again, there are no clinical data with this substance so far.
Since ANGPTL3 regulates TGs metabolism in part by inhibiting LPL, loss-of-function 
variants in the ANGPTL3 gene are associated with decreased plasma levels of TGs, LDL-C, 
and HDL-C. Therefore, ANGPTL3 is considered an important new potential target for the 
treatment of lowering TGs and LDL-C and thus prevention of CVD. A monoclonal antibody 
against ANGPTL3 (REGN1500) called evinacumab was developed and it has been shown in 
an early phase trial that it can substantially lower elevated TGs levels.140)141) Also, in a phase 
I trial, it has been demonstrated that administration of a second-generation antisense 
oligonucleotide targeting ANGPTL3 (IONIS-ANGPTL3Rx) during 6 weeks resulted in a dose-
dependent reduction of plasma ANGPTL3 and TGs in healthy individuals.142) The most recent 
approach is based upon a CRISPR/Cas mechanism and it is still under development but the 
initial results are encouraging.143) Apart from the effect of ANGPTL3 on lipid metabolism, it 
has been suggested that this substance might have additional anti-atherosclerotic effects, 
such as an anti-inflammatory, anti-angiogenic, and an increase of macrophage cholesterol 
efflux. Several years ago antibodies against ANGPTL4 were also shown to interfere with the 
inactivation of LPL. For ANGPTL4 there are two reported mutations (P251T and R371Q) 
which are linked to elevated plasma TGs levels.144) Therefore monoclonal antibodies against 
ANGPTL4 might also be promising targets for lowering elevated TGs.145) ANGPTL8 inhibitors 
might also be promising for lowering elevated TGs but even more for treatment of NAFLD.146) 
GPIHBP1 could also be a possible drug development target but there are still no reports 
dealing with this.
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CONCLUSION
Most recent data strongly favor the role of elevated plasma levels of TG-rich particles as 
an independent risk factor for CVD and there are more and more data that it could be a 
causal risk factor as well. Results of many large observational, epidemiological, genetic 
and Mendelian randomization studies support the claims that elevated TGs are associated 
with increased risk for CVD and indicate that therapeutic targeting of them could possibly 
provide further benefit in reducing CVD morbidity, events and mortality, apart from LDL-C 
lowering. At the moment besides lifestyle changes which can be very effective, much 
more than in lowering elevated LDL-C, fibrates are the drugs of choice for treatment of 
hypertriglyceridemia. 2–4 mg of omega-3 fatty acids could be added as combined treatment 
but there is no evidence that this combination alone or on background of statins can reduce 
CVD morbidity and mortality. There are also some new drugs which might be important 
in reducing elevated TG-rich particles. Volanesorsen, is an antisense oligonucleotide that 
inhibits the production of the Apo C-III which is crucial in regulating TGs metabolism 
because it inhibits LPL and HL activity but also hepatic uptake of TGs-rich particles. 
Evinacumab is a monoclonal antibody against ANGPTL3 and it seems that it can substantially 
lower elevated TGs levels because ANGPTL3 also regulates TGs metabolism. Pemafibrate is 
a selective peroxisome proliferator-activated receptor alpha modulator which also decreases 
TGs, and improves other lipid parameters without increasing adverse effects, as compared 
to placebo and fenofibrate. It is important to stress that most probably pemafibrate also 
enhances reverse cholesterol transport from macrophages to HDL particles and exerts 
anti-inflammatory activities thus possibly retarding the progression and even promoting 
the regression of atherosclerosis. Alipogene tiparvovec is a nonreplicating adeno-associated 
viral vector that delivers copies of the LPL gene to muscle tissue which accelerates the 
clearance of TG-rich lipoproteins thus decreasing extremely high TGs levels. Pradigastat is 
a novel diacylglycerol acyltransferase 1 inhibitor which substantially reduces extremely high 
TGs levels and appears to be promising in treatment of the rare familial chylomicronemia 
syndrome. Still more evidence is needed to prove beyond any doubt that lowering TG-rich 
lipoproteins with any of these substances can save lives since CVD outcome studies with all 
TGs-lowering agents have so far produced inconsistent results.
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